NCT03758612 - A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of TBI-223 in Healthy Adults | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 16, 2019

Primary Completion Date

March 15, 2020

Study Completion Date

March 15, 2020

Conditions

TuberculosisTuberculosis, Pulmonary

Interventions

DRUG

TBI-223 oral suspension

TBI-223 oral suspension, orally administered.

DRUG

TBI-223 enteric capsule

TBI-223 enteric capsules filled with 150 mg of TBI-223 powder, orally administered.

DRUG

TBI-223 SR Tablet Prototype 1

TBI-223 600 mg sustained-release (SR) tablet Prototype 1, orally administered.

DRUG

TBI-223 SR Tablet Prototype 2

TBI-223 600 mg SR tablet Prototype 2, orally administered.

DRUG

TBI-223 SR Tablet Prototype 3

TBI-223 900 mg SR tablet Prototype 3, orally administered.

DRUG

TBI-223 IR Tablet

TBI-223 1000 mg immediate release (IR) tablet, orally administered

DRUG

Placebo suspension

Placebo for TBI-223 oral Suspension; orally administered.

Trial Locations (1)

Worldwide Clinical Trials (WCT), San Antonio

All Listed Sponsors

lead

Global Alliance for TB Drug Development

OTHER